Sign In
Buy RMD
$188.63
+2.34 (+1.26%)
At Close: Jun 18, 2026
ResMed Q3 Earnings and Revenues Beat, Stock Up in After-Market
08:25am, Thursday, 24'th Apr 2025
RMD's stellar third-quarter fiscal 2025 results reflect the ongoing momentum and strong execution across all areas of its business.
ResMed: Cornering The Market In Sleep Solutions
05:12am, Thursday, 24'th Apr 2025
ResMed is a dominant player in healthcare devices with strong margins, recurring revenues, and a near-monopoly, offering a compelling mix of value and growth. The company continually invests in R&D, e
ResMed Inc. (RMD) Q3 2025 Earnings Call Transcript
07:16pm, Wednesday, 23'rd Apr 2025
ResMed Inc. (NYSE:RMD ) Q3 2025 Earnings Conference Call April 23, 2025 4:30 PM ET Company Participants Mick Farrell - Chairman & Chief Executive Officer Salli Schwartz - Chief Investor Relations Offi
Here's What Key Metrics Tell Us About ResMed (RMD) Q3 Earnings
07:00pm, Wednesday, 23'rd Apr 2025
Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street es
ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates
06:20pm, Wednesday, 23'rd Apr 2025
ResMed (RMD) came out with quarterly earnings of $2.37 per share, beating the Zacks Consensus Estimate of $2.36 per share. This compares to earnings of $2.13 per share a year ago.
ResMed slightly beats quarterly profit estimates on sleep devices demand
05:08pm, Wednesday, 23'rd Apr 2025
Resmed beat Wall Street estimates for third-quarter profit on Wednesday, driven by demand for its sleep apnea devices used to manage the common sleep disorder.
Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2025
04:05pm, Wednesday, 23'rd Apr 2025
Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
Resmed Names Salli Schwartz as Chief Investor Relations Officer
05:00pm, Monday, 21'st Apr 2025
Former Illumina, MSCI, and Moody's executive brings extensive experience leading engagement with the global investment community Former Illumina, MSCI, and Moody's executive brings extensive experienc
What Analyst Projections for Key Metrics Reveal About ResMed (RMD) Q3 Earnings
10:20am, Thursday, 17'th Apr 2025
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for ResMed (RMD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quar
ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth
11:06am, Wednesday, 16'th Apr 2025
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why ResMed (RMD) is a Strong Growth Stock
10:45am, Tuesday, 15'th Apr 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Strength Seen in ResMed (RMD): Can Its 3.8% Jump Turn into More Strength?
09:41am, Tuesday, 08'th Apr 2025
ResMed (RMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
RMD Stock Benefits From the Launch of NightOwl Across US
09:10am, Friday, 04'th Apr 2025
Resmed launches NightOwl, an FDA-cleared home sleep apnea test, in the United States to diagnose OSA at home.
Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, Now Available Across the US
09:00am, Thursday, 03'rd Apr 2025
SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced its home
Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025
04:05pm, Wednesday, 02'nd Apr 2025
SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2025 on Wednesday,
